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Abstract
Multiple sclerosis (MS) is a convoluted autoimmune and inflammatory disease of the
central nervous system (CNS) in which the protective myelin sheath is eroded and
the underlying nerve fibers are damaged. There is no conclusive knowledge on the
role  played  by  different  etiological  factors  in  its  development,  and  studies  have
shown  that  it  primarily  results  due  to  complex  interactions  between  the  genetic,
geographic and infectious components.  Among the risk factors reported to have a
possible  role  in  MS development,  retroviruses  also  appear  to  influence it.  Studies
suggest human immunodeficiency virus (HIV) infection to be inversely related to MS
risk,  but  to date,  the association between the two remains enigmatic.  This  protec‐
tive inverse association has become an area of active research and the most plausible
explanations  for  this  may  be  immune  suppression  and/or  antiretroviral  medica‐
tions. The purpose of writing this chapter is to provide background information on
the unfathomable relationship between HIV infection and the risk of developing MS
while at the same time providing description of the insights garnered from recent
studies. While highlighting the application of ART (antiretroviral therapy) as budding
future alternative for MS management, this chapter provides momentum for further
studies.
Keywords: multiple sclerosis, etiology, human immunodeficiency virus, epidemiolo‐
gy, ART
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1. Introduction
Multiple sclerosis (MS) is a complex, debilitating neurologic disease characterized by demye‐
lination of axons in the brain and spinal cord and caused by an immune attack against the myelin
sheath. The disease is highly prevalent in North America and Europe (>100/100,000 inhabi‐
tants). According to the recently revised 2013 Atlas of MS published by the World Health
Organization (WHO) and Multiple Sclerosis International Federation (MSIF) (http://www.atlas‐
ofms.org), the prevalence rate of 5–20 per 100,000 has been reported for India. Clinically, MS is
characterized by a broad spectrum of symptoms [1]. It has autoimmune and inflammatory
components, with intense effects on the communication between nerve cells within the brain
and spinal cord [1]. The different types of MS vary in terms of severity, prevalence, and degree
of progression [2, 3]. The most common phenotype is relapsing remitting (RR) MS, followed by
secondary progressive (SP) and then primary progressive (PP). Less prevalent phenotypes have
also been reported [2]. MS pathology is characterized by inflammatory plaques caused by
demyelination of axons in the central nervous system (CNS). Due to the presence of immune-
inflammatory characteristics in MS, treatments targeting T lymphocyte and natural killer (NK)
cell activation seem to play a significant role [4].
With intangible and enigmatic etiology having both genetic and environmental backgrounds,
MS offers a profound conundrum. Yet, despite incomplete understanding of the basic
mechanisms behind its pathogenesis, a growing body of evidence suggests heterogeneous
etiology of MS with multiple environmental factors contributing to its development [5–7].
Various studies suggest that intricate interactions between genetic factors and environmental
factors elicit it; thus, genetically susceptible individuals who encounter a number of environ‐
mental and epigenetic factors are at higher risk (Figure 1) [8, 9].
Figure 1. Multiple sclerosis as a complex neurological condition affecting CNS: The etiology of MS is unknown and
enigmatic; however, it has a profound role of numerous environmental and genetic components, and multiplex inter‐
actions between them lead to its development, thus making it a multifactorial and polygenic heterogeneous disease.
Some risk factors, which have been studied in various populations, include geographic
location [10, 11], wheat consumption [11, 12], dairy product consumption [13, 14], fish intake
[15], animal fat intake [15], high ultraviolet radiation [16–18], vitamin D deficiency [19], and
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viral infection [20–22]. The likely association between genetic and infectious components in
MS development is shown by the human endogenous retroviruses (HERVs) [23, 24]. Although
many viruses have raised suspicions as responsible for MS, not all studies confirm their
etiologic role. Thus, each virus has chalked up another obstruction in the MS conundrum.
There is escalating evidence suggesting a retroviral connection to MS risk, and the most
noteworthy among them is human immunodeficiency virus (HIV). Studies suggest HIV
infection to be inversely related to MS risk [25–27] but, to date, the association between the
two remains enigmatic [28]. The purpose of this chapter is to provide an overview of the
insights garnered from recent studies on the association between HIV and MS risk. While
highlighting this association, the main objective of this chapter is to provide an impetus for
future studies aimed at precisely establishing the mechanism behind the impact of HIV on MS.
2. Link between HIV and MS risk
The epidemiology of MS shows a latitudinal gradient, and its risk is governed by genetic
predisposition as well as local environmental conditions (Figure 1). Even though its etiology
remains uncertain, quite a few studies have suggested involvement of a virus in its pathogen‐
esis. For example, the association between genetic and infectious components in MS develop‐
ment is suggested by the HERV, which constitutes about 8–30% of the human genome with
approximately 98,000 elements [29]. Until 2005, however, no HERVs capable of replication had
been identified, only traces of original viruses were identified [30]. were identified. Only one
family of HERV viruses has been active, the HERV-K family, comprising <1% of total HERV
elements [29, 30]. This family is a candidate for playing a fundamental role in MS pathophysi‐
ology. Evidence for this role includes studies that have shown activation of T-cell response
against HERV in individuals infected with HIV [31]. This has formed the much needed ground
for alternative drug therapy targeted against HERV for elimination of HIV, and it might
therefore aid in using HERV proteins as markers for drug designing instead of frequently
mutating HIV antigens. One of the HERV proteins reported to be expressed in the active lesions
of MS is the MS-associated retrovirus envelope protein (MSRV-Env) [32–34]. There is accu‐
mulating evidence suggesting an inverse association between HIV and MS, and large-scale
epidemiological studies have supported this notion. Studies have found significantly lower
prevalence of MS in people with HIV infection [26]; moreover, there has been only a single
case report of MS treatment with antiretroviral drugs in an HIV patient.
With the help of population-based databases, a recent study demonstrated reduced incidence
of MS in HIV patients; however, due to a smaller sample size, it proved statistically insignifi‐
cant [26]. Gold et al. [25] investigated a much larger sample and revealed a statistically
significant negative relationship between HIV and MS, reflecting a protective effect of HIV on
MS. Still unclear is the exact mechanism behind this association. The protection HIV provides
against MS may be mediated by suppression of the immune system due to chronic HIV
infection and antiretroviral medications, thus preventing MS progression or treating it
completely (Figure 2). To date, it is not known whether HIV per se, application of antiretroviral
therapy (ART), or a combination of the two diminishes MS symptoms. The most plausible
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explanation for this protective effect may be HIV-induced immunodeficiency targeting a wide
continuum of immune cells and signal transduction pathways involved in MS pathogenesis.
Alternatively, antiretroviral medications used against HIV may target other viruses involved
in MS pathogenesis such as, HERV and herpes.
Figure 2. Protective inverse relationship between MS and HIV: HIV infection leads to reduced MS risk, which may be
attributed to constant suppression of the immune system by HIV-induced immunodeficiency targeting diverse spec‐
trum of immune cells and signal transduction pathways involved in MS pathogenesis, and/or antiretroviral drugs used
to treat the infection, thus preventing MS progression or treating it completely.
The big puzzle of whether and when to start HIV therapy in MS patients remains blurred.
Previous studies based on case report and data linkage studies presumed that protective
infection was conferred against MS development due to ART treatment rather than HIV
infection per se. However, in neither case has systematic description been offered about the
individuals who were treated with ART and those who were not [27]. There are still different
opinions on early [35] and late treatment options due to different aspects such as side effects
and drug resistance [36]. Therefore, no clear-cut approach exists on starting ART. In these
studies, nothing has been mentioned about exposure to antiretroviral medications and its
duration [27]. Moreover, HIV and MS are often misdiagnosed due to the presence of MS-like
symptoms in HIV; therefore, focus should be on targeted treatments of MS patients with HIV
and vice versa. To fully understand the mechanism behind the apparently MS-protective
phenotype of HIV infection, the most plausible research approach would be analysis of data
on HIV patients with MS or vice versa and the details on influence of cotreatment with
antiretroviral medications and disease-modifying treatments (DMTs).
Due to the presence of immune-inflammatory characteristics in MS, treatments targeting T
lymphocyte activation may play a significant role. There is growing evidence that favors
suppression of MS pathology by employing anti-HIV therapy, and it has prompted one trial
in MS patients for the drug Raltegravir (Isentress) [37] used in HIV treatment and also an
immunoglobulin G4 monoclonal antibody called GNbAC1 [4, 38–40] against HERV proteins.
The association between HIV and MS can be exploited to replace conventional treatment
options for MS by formulating new safe, effective, and long-term therapeutic alternatives.
Further investigations are mandatory to provide a deeper insight into the mechanism of action
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for HIV/ART on MS risk, and this can be fulfilled by carrying out large-scale clinical, molecular,
as well as epidemiological studies.
3. Conclusion
Despite the extensive research on MS, its exact etiology remains hard to pin down. Neverthe‐
less, epidemiological findings across the globe suggest its association with specific retroviruses
endogenous to humans. Regardless of the paucity of reports on HIV and MS association, this
finding appears to be crucial in the etiology of MS. A comprehensive understanding of this
link is needed to elucidate the complex interactions between HIV and MS and also to exploit
HIV’s protective role in order to develop treatments for MS. Research that unscrambles the
relation between the two would, at the same time, provide new insights into the etiopatho‐
genesis of MS and provide therapeutic targets and strategies.
Nevertheless, additional studies on mechanisms of interaction between HIV and MS are
required to determine the underlying mediators of this protective association and eventually
endow insight into the disease pathogenesis as well as its management. To date, the studies
in this milieu hitherto are insufficient, and there is extreme need for an extensive upsurge in
large-scale conclusive molecular and epidemiological studies. It is noteworthy that this chapter
further enlightens the acuity of an association between HIV (or its treatment) and a reduced
risk of developing MS; however, it is flagrant that this association needs to be examined
skeptically in order to gain deeper insight into this enigmatic relationship. The need of hour
is to establish precisely whether having HIV, being treated for HIV with antiretroviral drugs,
or a combination of the two reduces the risk of developing MS, which will certainly open the
door for developing better and more promising treatment options for MS.
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